LAPSE:2023.28328
Published Article
LAPSE:2023.28328
Production of High-Value Proteins under Stringent Cost Constraints—The Case of Hollow Fiber Technology for Cell Culture
Faifan Tantakitti, Supansa Pata, Witida Laopajon, Watchara Kasinrerk, Araida Hidalgo-Bastida
April 11, 2023
For decades, the benefits of utilizing hollow fiber bioreactors for continuous cell culture to produce monoclonal antibodies have been widely recognized. However, the suitability of this technology for laboratories or centers with limited resources and expertise seeking to expand their production capacity is uncertain, mainly due to unknown cost-effectiveness. In this study, a hollow fiber bioreactor with a 4.7-mL culture volume was used to culture a hybridoma clone producing immunoglobulin G antibody specific to hemoglobin F (HbF). The antibody reached a maximum concentration of 1.22 g/L and totaled 21 mg over a 44-day culture period. This preliminary production data was used to estimate the cost of consumables required for using the hollow fiber bioreactor to produce 130 mg of monoclonal antibodies, which was found to be THB35.8k (£880). The cost was slightly more expensive than batch cultivation in typical culture dishes, which ranged from THB27.8 to 30.2k (£680 to 740). Despite the advantages in terms of reduced hands-on time, shorter production duration, and highly concentrated products, the primary challenges associated with using hollow fiber bioreactors were the cost and availability of the cartridges.
Keywords
cost analysis, hemoglobin f, hollow fiber bioreactor, hybridoma, monoclonal antibody production, upstream process
Subject
Suggested Citation
Tantakitti F, Pata S, Laopajon W, Kasinrerk W, Hidalgo-Bastida A. Production of High-Value Proteins under Stringent Cost Constraints—The Case of Hollow Fiber Technology for Cell Culture. (2023). LAPSE:2023.28328
Author Affiliations
Tantakitti F: Department of Mechanical Engineering, Faculty of Engineering, Chiang Mai University, Chiang Mai 50200, Thailand; Center of Excellence in Materials Science and Technology, Chiang Mai University, Chiang Mai 50200, Thailand [ORCID]
Pata S: Division of Clinical Immunology, Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai 50200, Thailand; Biomedical Technology Research Center, National Center for Genetic Engineering and Biotechnology,
Laopajon W: Division of Clinical Immunology, Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai 50200, Thailand; Biomedical Technology Research Center, National Center for Genetic Engineering and Biotechnology, [ORCID]
Kasinrerk W: Division of Clinical Immunology, Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai 50200, Thailand; Biomedical Technology Research Center, National Center for Genetic Engineering and Biotechnology,
Hidalgo-Bastida A: Centre of Biomedicine, Department of Life Sciences, Manchester Metropolitan University, Manchester M1 5GD, UK [ORCID]
Journal Name
Processes
Volume
11
Issue
3
First Page
889
Year
2023
Publication Date
2023-03-15
Published Version
ISSN
2227-9717
Version Comments
Original Submission
Other Meta
PII: pr11030889, Publication Type: Journal Article
Record Map
Published Article

LAPSE:2023.28328
This Record
External Link

doi:10.3390/pr11030889
Publisher Version
Download
Files
[Download 1v1.pdf] (1.8 MB)
Apr 11, 2023
Main Article
License
CC BY 4.0
Meta
Record Statistics
Record Views
84
Version History
[v1] (Original Submission)
Apr 11, 2023
 
Verified by curator on
Apr 11, 2023
This Version Number
v1
Citations
Most Recent
This Version
URL Here
https://psecommunity.org/LAPSE:2023.28328
 
Original Submitter
Auto Uploader for LAPSE
Links to Related Works
Directly Related to This Work
Publisher Version